You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
Analysis tamoxifen, endoxifen, and 4-hydroxytamoxifen in dbs of breast cancer patients by lc-ms/ms
- In: D25 What’s new in industry & science? Part 2 on Thursday, 6 September 2018, 09:10 -09:20
- At: Glasgow (Scotland) (2018)
- Type: Presentation
- By: HARAHAP, Yahdiana (Universitas Indonesia, Indonesia)
- Co-author(s): Yahdiana Harahap
Baitha Palanggatan Maggadani: Pharmacy, Universitas Indonesia, Depok, Indonesia
Tesanika Ribka Joulin Sitorus: Pharmacy, Universitas Indonesia, Depok, Indonesia
Callista Andinie Mulyadi: Pharmacy, Universitas Indonesia, Depok, Indonesia
Denni Joko Purwanto: Dharmais Cancer Hospital, Dharmais Cancer Hospital, Jakarta, Indonesia - Abstract:
Background
The antiestrogen effect of tamoxifen is highly determined by its active metabolites, 4-Hydroxytamoxifen (endoxifen) and 4-Hydroxy-N-Desmethyltamoxifen (4-OHTAM). Monitoring concentration of analyte and metabolites in DBS helps to improve effectiveness of therapy by minimizing drug toxicity and ensuring appropriate dosage regiment with
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026